GB2209939B - The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents - Google Patents

The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents

Info

Publication number
GB2209939B
GB2209939B GB8821104A GB8821104A GB2209939B GB 2209939 B GB2209939 B GB 2209939B GB 8821104 A GB8821104 A GB 8821104A GB 8821104 A GB8821104 A GB 8821104A GB 2209939 B GB2209939 B GB 2209939B
Authority
GB
United Kingdom
Prior art keywords
prostaglandins
keto
dihydro
hypotensive agents
ocular hypotensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8821104A
Other languages
English (en)
Other versions
GB2209939A (en
GB8821104D0 (en
Inventor
Ryuzo Ueno
Ryuji Ueno
Tomio Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26532381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2209939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ueno Seiyaku Oyo Kenkyujo KK, R Tech Ueno Ltd filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of GB8821104D0 publication Critical patent/GB8821104D0/en
Publication of GB2209939A publication Critical patent/GB2209939A/en
Application granted granted Critical
Publication of GB2209939B publication Critical patent/GB2209939B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB8821104A 1987-09-18 1988-09-08 The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents Expired - Lifetime GB2209939B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23589087 1987-09-18
JP33403787 1987-12-29

Publications (3)

Publication Number Publication Date
GB8821104D0 GB8821104D0 (en) 1988-10-05
GB2209939A GB2209939A (en) 1989-06-01
GB2209939B true GB2209939B (en) 1992-01-02

Family

ID=26532381

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8821104A Expired - Lifetime GB2209939B (en) 1987-09-18 1988-09-08 The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents

Country Status (11)

Country Link
US (1) US5001153A (enExample)
EP (2) EP0455264B1 (enExample)
JP (2) JPH02108A (enExample)
KR (1) KR930000051B1 (enExample)
AT (2) ATE108330T1 (enExample)
CA (1) CA1328075C (enExample)
DE (2) DE3876050T2 (enExample)
ES (1) ES2052735T3 (enExample)
GB (1) GB2209939B (enExample)
GR (1) GR3006319T3 (enExample)
NZ (1) NZ226197A (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2186670T3 (es) * 1988-09-06 2003-05-16 Pharmacia Ab Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
EP1300149A3 (en) * 1988-09-06 2003-05-14 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0580268B1 (en) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Ocular hypotensive agents
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
DE69019431T2 (de) * 1989-07-27 1995-09-14 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
AU640767B2 (en) * 1990-03-08 1993-09-02 Shionogi & Co., Ltd. 15-deoxyprostaglandin derivative
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
EP0458590B1 (en) * 1990-05-22 1996-01-10 R-Tech Ueno Ltd. Treatment of ocular hypertention with a synergistic combination
DK0458589T3 (da) * 1990-05-22 1995-04-03 R Tech Ueno Ltd Behandling af okulær hypertension med en okulær synergistisk kombination
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
DK0458587T3 (da) * 1990-05-22 1993-08-23 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
CA2042972C (en) * 1990-05-22 1996-10-15 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ocular administration
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
TW210287B (enExample) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
US5221690A (en) * 1991-10-02 1993-06-22 R-Tech Ueno Ltd. Increasing the choroidal blood flow
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
FR2707295A1 (fr) * 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5387608A (en) * 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
CA2138181A1 (en) * 1993-12-15 1995-06-16 Verney L. Sallee Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
EP0944593A2 (en) 1996-11-12 1999-09-29 Alcon Laboratories, Inc. $i(CIS)-$g(D)?4 ANALOGS OF PROSTAGLANDINS AS OCULAR HYPOTENSIVES
US6649653B1 (en) 1996-11-12 2003-11-18 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
EP1021179B1 (en) 1997-02-04 2004-05-12 Murray A. Johnstone Method of enhancing hair growth
US6172109B1 (en) 1997-03-07 2001-01-09 Alcon Laboratories, Inc. 13-Thia prostaglandins for use in glaucoma therapy
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
DE69834638T2 (de) 1997-10-13 2007-05-10 R-Tech Ueno, Ltd. Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
DE69829227D1 (de) * 1998-12-25 2005-04-07 Sucampo A G Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
SE9900672D0 (sv) 1999-02-25 1999-02-25 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
WO2001046134A1 (en) * 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
JP2003520245A (ja) * 2000-01-18 2003-07-02 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科組成物
IL151683A0 (en) * 2000-03-16 2003-04-10 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
CN1443070A (zh) * 2000-03-24 2003-09-17 苏坎波公司 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
WO2003077845A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
WO2003103664A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2003105847A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1515722A4 (en) * 2002-06-17 2006-06-21 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
CA2488752A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
CA2488884A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
WO2004019951A1 (ja) * 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
CA2502914A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
CA2506464C (en) 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
WO2004087051A2 (en) * 2003-03-27 2004-10-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1666043B1 (en) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
ES2331313T3 (es) * 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. Composicion farmaceutica que contiene prostaglandina.
US20080139648A1 (en) * 2004-12-09 2008-06-12 Santen Pharmaceutical Co., Ltd. Product Containing Prostaglandin Having Fluorine Atom In Its Molecule
WO2006068266A1 (ja) * 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
JP4892483B2 (ja) * 2004-12-29 2012-03-07 株式会社アールテック・ウエノ 頭皮および毛髪の処置のための組成物および方法
TWI432201B (zh) * 2005-03-04 2014-04-01 Sucampo Ag 11-去氧基-前列腺素化合物用於治療週邊血管疾病之用途
JP4648340B2 (ja) * 2006-02-07 2011-03-09 株式会社アールテック・ウエノ １５−ケトプロスタグランジンｅ誘導体の製造法
US20090062381A1 (en) * 2006-03-13 2009-03-05 Ryu Hirata Aqueous composition
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
UA103616C2 (ru) 2008-04-24 2013-11-11 Аллерган, Инк. Замещенные гамма-лактамы как терапевтические агенты
US7713968B2 (en) 2008-04-24 2010-05-11 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2498783B1 (en) 2009-11-09 2018-08-22 Allergan, Inc. Compositions and methods for stimulating hair growth
WO2012018324A1 (en) 2010-08-02 2012-02-09 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
TW202239413A (zh) 2011-02-04 2022-10-16 日商興和股份有限公司 眼科用製劑
WO2012137987A1 (en) 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
EA034839B1 (ru) 2014-10-20 2020-03-26 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284180A1 (en) * 1987-01-28 1988-09-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476661A (en) * 1974-05-13 1977-06-16 American Cyanamid Co Prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0643313B2 (ja) * 1986-03-13 1994-06-08 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) * 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
JPS6453101A (en) * 1987-05-25 1989-03-01 Kurashiki Boseki Kk Equal tilt angle interference type film thickness gauge
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284180A1 (en) * 1987-01-28 1988-09-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Arch. int. Pharmacodyn 1974,207,131-138 *

Also Published As

Publication number Publication date
DE3850676D1 (de) 1994-08-18
KR890004707A (ko) 1989-05-09
ES2052735T3 (es) 1994-07-16
US5001153A (en) 1991-03-19
JPH0571567B2 (enExample) 1993-10-07
ATE108330T1 (de) 1994-07-15
EP0455264A3 (en) 1991-11-27
JP2592204B2 (ja) 1997-03-19
JPH02108A (ja) 1990-01-05
GB2209939A (en) 1989-06-01
EP0308135A3 (en) 1989-06-14
EP0308135A2 (en) 1989-03-22
DE3876050T2 (de) 1993-03-25
GB8821104D0 (en) 1988-10-05
AU2231388A (en) 1989-03-23
GR3006319T3 (enExample) 1993-06-21
CA1328075C (en) 1994-03-29
AU600168B2 (en) 1990-08-02
EP0455264A2 (en) 1991-11-06
DE3850676T2 (de) 1994-11-03
KR930000051B1 (ko) 1993-01-06
NZ226197A (en) 1992-02-25
EP0308135B1 (en) 1992-11-19
EP0455264B1 (en) 1994-07-13
ATE82499T1 (de) 1992-12-15
DE3876050D1 (de) 1992-12-24
JPH0680571A (ja) 1994-03-22

Similar Documents

Publication Publication Date Title
GB2209939B (en) The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
TW218869B (enExample)
BR1100989A (pt) Composto e composição de matéria
EG18729A (en) Compound of n- amino - 1,2,4-triazinones used as insecticide.
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
ZA893346B (en) Anticoagulant peptide alcohols
GR3006694T3 (enExample)
AP8800109A0 (en) "Heterocyclic insecticides".
UA37239C2 (uk) Хлорметилдіарилоксирани
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
IT8420775V0 (it) Corpo musicale, nonche' di illuminazione, automatico.
ZA929176B (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b e)azepine-6,11-dione-11-oximes.
DE3776488D1 (enExample)
AU2196188A (en) 1(2h)-phthalazinones as cytoprotective agents
LT2342B (lt) 2,6-dioksopiperazino gavimo budas
IT8619209A0 (it) Procedimento per l'epossidazione di composti olefinici.

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PE20 Patent expired after termination of 20 years

Expiry date: 20080907